The Oxygen Study

Study Objective:

• The study medication is a potential new treatment for Idiopathic Pulmonary Fibrosis (IPF), administered via an inhaled solution, participants will receive one dose.
• Around 2,170 Australian's are diagnosed with IPF each year. IPF is an irreversible, progressive, and usually fatal lung disease characterized by fibrosis of the lung tissues and progressive loss of lung function.
• Fibrosis is when excess scar tissue forms in the body making it hard for the organs like the lungs to work properly.

Importance of Treatment:

• Despite the availability of current treatments, there is still no cure for IPF, and further treatment options are desperately needed.
• Your involvement could play a crucial role in advancing IPF treatment and potentially transforming the lives of those affected by this condition.

Clinical Trial Details:

• An independent ethics committee has approved this clinical trial.
• Participants will be reimbursed for their time
  

Call us on 1800 243 733 to discuss your eligibility today!